Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropathol Appl Neurobiol ; 27(3): 206-14, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11489140

ABSTRACT

Mitochondrial abnormalities, in particular the accumulation of mitochondrial DNA mutations, have been proposed as a potential cause of normal ageing. One group of patients with mtDNA disorders have a nuclear DNA defect which accelerates the chronological accumulation of mitochondrial DNA mutations. These patients provide an ideal means of investigating whether accelerated mitochondrial DNA defects can cause accelerated ageing pathology. The choroid plexus demonstrates a robust accumulation of pathological changes, in the form of Biondi bodies, with normal ageing. We have therefore examined the choroid plexus of a case with multiple mitochondrial DNA deletions for evidence of accelerated ageing and compared it with two cases with point mutation mitochondrial DNA disorders and several age-matched and elderly controls with and without clinical and neuropathological evidence of neurodegenerative disease. We also demonstrate that the choroid plexus of the mitochondrial DNA cases contain cells with levels of mitochondrial DNA mutation sufficient to cause a biochemical deficiency in the oxidative phosphorylation pathway. As previously reported, both cases with point mutation mitochondrial DNA disorders exhibit a characteristic oncocytic type transformation of the choroidal epithelial cells. However, in the case with multiple mitochondrial DNA deletions we demonstrate pathological changes in choroid plexus that are strongly suggestive of accelerated ageing. We believe that this finding supports the theory that the accumulation of mitochondrial DNA mutations can lead to pathological changes typical of ageing cells.


Subject(s)
Aging/physiology , Choroid Plexus/pathology , DNA, Mitochondrial/genetics , Gene Deletion , Adult , Female , Humans , Male , Middle Aged , Mitochondrial Myopathies/genetics , Mitochondrial Myopathies/pathology , Point Mutation , Time Factors
2.
Nucleic Acids Res ; 29(16): 3404-12, 2001 Aug 15.
Article in English | MEDLINE | ID: mdl-11504878

ABSTRACT

Mutations in mitochondrial DNA (mtDNA) cause a spectrum of human pathologies, which predominantly affect skeletal muscle and the central nervous system. In patients, mutated and wild-type mtDNAs often co-exist in the same cell (mtDNA heteroplasmy). In the absence of pharmacological therapy, a genetic strategy for treatment has been proposed whereby replication of mutated mtDNA is inhibited by selective hybridisation of a nucleic acid derivative to the single-stranded replication intermediate, allowing propagation of the wild-type genome and correction of the associated respiratory chain defect. Previous studies have shown the efficacy of this anti-genomic approach in vitro, targeting pathogenic mtDNA templates with only a single point mutation. Pathogenic molecules harbouring deletions, however, present a more difficult problem. Deletions often occur at the site of two short repeat sequences (4-13 residues), only one of which is retained in the deleted molecule. With the more common larger repeats it is therefore difficult to design an anti-genomic molecule that will bind selectively across the breakpoint of the deleted mtDNA. To address this problem, we have used linker-substituted oligodeoxynucleotides to bridge the repeated residues. We show that molecules can be designed to bind more tightly to the deleted as compared to the wild-type mtDNA template, consistent with the nucleotide sequence on either side of the linker co-operating to increase binding affinity. Furthermore, these bridging molecules are capable of sequence-dependent partial inhibition of replication in vitro.


Subject(s)
DNA Replication , DNA, Mitochondrial/biosynthesis , DNA, Mitochondrial/genetics , Oligodeoxyribonucleotides/metabolism , Sequence Deletion/genetics , Base Pairing , Base Sequence , Biotinylation , DNA, Mitochondrial/chemistry , DNA, Mitochondrial/metabolism , DNA, Single-Stranded/chemistry , DNA, Single-Stranded/genetics , DNA, Single-Stranded/metabolism , Genome , Humans , Kinetics , Mitochondrial Myopathies/genetics , Mitochondrial Myopathies/therapy , Nucleic Acid Denaturation , Oligodeoxyribonucleotides/chemistry , Oligodeoxyribonucleotides/genetics , Substrate Specificity , Surface Plasmon Resonance , Templates, Genetic , Thermodynamics
3.
Adv Drug Deliv Rev ; 49(1-2): 121-5, 2001 Jul 02.
Article in English | MEDLINE | ID: mdl-11377807

ABSTRACT

In mammals, mitochondrial DNA (mtDNA) is the only autonomously replicating source of DNA outside the nucleus. Housed in the mitochondrial matrix, this molecule encodes thirteen polypeptides, all of which are believed to be essential components of the mitochondrial respiratory chain. Defects of the mitochondrial genome can cause severe neurological and multi-systemic disorders. As the genetic defect causes a dysfunction in the terminal stage of oxidative metabolism, there is little potential for pharmacological intervention. Thus, there is currently no effective therapy for these chronic progressive disorders. In the disease state, pathogenic mtDNA molecules often cohabit the same cell and tissue with wild type mtDNA, a situation termed heteroplasmy. Manifestation of biochemical and clinical defects occur only when a threshold level of heteroplasmy has been passed. The mitochondrial genome must be continually turned over. Consequently, if a pathogenic mtDNA molecule were to be targeted to prevent it from replicating, the wild type copy would be given a propagative advantage. Over time, therefore, the biochemical and, potentially, the clinical deficiency could be reversed. This manuscript summarises our attempts to identify such an antigenomic molecule, to localise this molecule to mitochondria and to assess its function in whole cells. Finally, we discuss the importance of identifying and designing new antigenomic molecules which may prove effective in treating patients with disorders of the mitochondrial genome.


Subject(s)
DNA, Mitochondrial/genetics , Gene Targeting/methods , Mitochondrial Myopathies/drug therapy , Peptide Nucleic Acids/therapeutic use , DNA Replication , DNA, Mitochondrial/drug effects , Humans , Mitochondrial Myopathies/genetics , Peptide Nucleic Acids/pharmacology
4.
Ann Neurol ; 48(2): 188-93, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10939569

ABSTRACT

During the past decade, there have been many descriptions of patients with neurological disorders due to mitochondrial DNA (mtDNA) mutations, but the extent and spectrum of mtDNA disease in the general population have not yet been defined. Adults with suspected mtDNA disease in the North East of England were referred to a single neurology center for investigation over the 10-year period from 1990 to 1999 inclusive. We defined the genetic defect in these individuals. For the midyear period of 1997, we calculated the minimum point prevalence of mtDNA disease in the adults of working age (> 16-<60 years old for female subjects and <65 years old for male subjects) and the minimum prevalence of adults and children (<60 years for female subjects, <65 years for male subjects) at risk of developing mtDNA disease. mtDNA defects caused disease in 6.57 per 100,000 individuals in the adult population of working age, and 7.59 per 100,000 unaffected adults and children were at risk of developing mtDNA disease. Overall, 12.48 per 100,000 individuals in the adult and child population either had mtDNA disease or were at risk of developing mtDNA disease. These results reflect the minimum prevalence of mtDNA disease and pathogenic mtDNA mutations and demonstrate that pathogenic mtDNA mutations are a common cause of chronic morbidity. These findings have resource implications, particularly for supportive care and genetic counseling.


Subject(s)
DNA, Mitochondrial/genetics , Optic Atrophies, Hereditary/genetics , Point Mutation/genetics , Adolescent , Adult , Child , Child, Preschool , Female , Genotype , Humans , Male , Middle Aged , Optic Atrophies, Hereditary/epidemiology , Phenotype , Prevalence , Risk Factors , United Kingdom
5.
Neurol Sci ; 21(5 Suppl): S909-12, 2000.
Article in English | MEDLINE | ID: mdl-11382188

ABSTRACT

Mitochondrial DNA (mtDNA) is the only autonomously replicating source of DNA outside the nucleus. The mitochondrial genome encodes thirteen essential polypeptides of the mitochondrial respiratory chain. Defects of the mitochondrial genome can cause severe neurological and multi-systemic disorders. In many patients there is a mixture of mutated and wild-type mtDNA in the same cell (a situation termed heteroplasmy). In these patients the ratio of mutated to wild-type mtDNA is crucial and a biochemical defect only occurs with relatively high levels of mutated mtDNA within an individual cell. This threshold also seems to be critical in the development of mtDNA disease. Since the genetic defect causes a dysfunction in the terminal stage of oxidative metabolism, there is little potential for pharmacological intervention. Molecular techniques must be developed to reverse the ratio of mutated and wild-type mtDNA. In this paper we summarise our approach using both antigenomic peptide nucleic acids and cell necrosis.


Subject(s)
DNA, Mitochondrial/genetics , Mitochondria, Muscle/genetics , Mitochondrial Myopathies/genetics , Mitochondrial Myopathies/therapy , DNA, Mitochondrial/drug effects , Genetic Therapy , Humans , Mitochondria, Muscle/drug effects , Mitochondria, Muscle/metabolism , Mitochondrial Myopathies/metabolism , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiopathology , Mutation/drug effects , Mutation/physiology , Regeneration/drug effects , Regeneration/physiology
6.
Methods Mol Med ; 38: 245-64, 2000.
Article in English | MEDLINE | ID: mdl-22351280

ABSTRACT

Although the precise mechanisms of the aging process remain poorly understood, a plausible theory for cellular dysfunction and deterioration during aging involves mitochondria (1, 2). The major function of mitochondria is to generate energy for cellular processes in the form of ATP by oxidative phosphorylation. Mitochondria contain their own DNA (mtDNA), a small 16.5 kb circular molecule that encodes 13 essential polypeptides of the mitochondrial respiratory chain, as well as 2 rRNAs and 22 tRNAs required for intramitochondrial protein synthesis (3). The mitochondrial respiratory chain is a series of five, multisubunit protein complexes located within the inner mitochondrial membrane. The first four of these (complexes I-IV) reoxidize reduced cofactors (NADH and FADH(2)) generated by the oxidation of foodstuffs, thereby generating an electrochemical gradient across the inner mitochondrial membrane which is harnessed by the fifth complex, the ATP synthetase, to drive the formation of ATP.

SELECTION OF CITATIONS
SEARCH DETAIL
...